Cargando…
Abdominopelvic Lymphatic Drainage Area Irradiation for Consolidative Radiotherapy of Advanced Ovarian Carcinoma: Analysis of Clinical Application Efficacy and Dosimetric Verification
BACKGROUND: The aim of the study was to evaluate the efficacy of abdominopelvic lymphatic drainage area irradiation (APLN), instead of whole abdominal radiotherapy (WART), in the consolidative radiotherapy of advanced ovarian carcinoma patients. METHODS: We conducted a retrospective analysis collect...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elmer Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239501/ https://www.ncbi.nlm.nih.gov/pubmed/35837318 http://dx.doi.org/10.14740/wjon1454 |
_version_ | 1784737311173378048 |
---|---|
author | Shen, Jing Tao, Yin Jie Guan, Hui Zhen, Hong Nan Dong, Ting Ting Liu, Zhi Kai Zhang, Fu Quan |
author_facet | Shen, Jing Tao, Yin Jie Guan, Hui Zhen, Hong Nan Dong, Ting Ting Liu, Zhi Kai Zhang, Fu Quan |
author_sort | Shen, Jing |
collection | PubMed |
description | BACKGROUND: The aim of the study was to evaluate the efficacy of abdominopelvic lymphatic drainage area irradiation (APLN), instead of whole abdominal radiotherapy (WART), in the consolidative radiotherapy of advanced ovarian carcinoma patients. METHODS: We conducted a retrospective analysis collecting 99 patients with locally advanced ovarian cancer treated by APLN with 45 - 50 Gy/25- 28 fractions/5-7#, instead of WART. We evaluated the clinical outcome of APLN. Five patients were selected for dosimetric verifications verses WART (30 Gy/20 fractions). The normal tissue complication probability (NTCP) was calculated for the two treatment methods. RESULTS: The mean follow-up time was 64.10 months (5.5 - 113.2 months), after APLN consolidative radiotherapy, 1-, 3-, and 5-year overall survival (OS) was 87.9%, 81.3%, and 61.5%, median disease-free survival (DFS) was 40.8 months, 5-year local recurrence free survival (LRFS) was 75.9%, and 5-year distant metastasis free survival (DMFS) was 49.2%. One patient died due to intestinal perforation. Local recurrence in the area between WART and APLN was rare (3/99 patients). The number of surgical procedures < 2 was an independent risk factor for LRFS (P = 0.023). Dosimetric comparison showed that comparing with WART, APLN significantly reduced the organ at risk (OAR) dose: 25.37 ± 3.63 Gy (25%) for liver, 8.77 ± 5.03 Gy (25%) for kidney, 8.14 ± 1.51 Gy (25%) for small intestine, etc. NTCP was reduced by 0.04-1.04% for liver, kidney, and small intestine. CONCLUSION: For consolidative radiotherapy in locally advanced ovarian cancer, APLN (intensity-modulated radiotherapy 45 - 50 Gy/25 - 28 fractions) could be an alternative to WART, resulting in excellent LRFS and DFS, with acceptable toxicities, comparing with previous literature reports. Dosimetric analysis also showed the benefits of APLN in NTCP. |
format | Online Article Text |
id | pubmed-9239501 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elmer Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-92395012022-07-13 Abdominopelvic Lymphatic Drainage Area Irradiation for Consolidative Radiotherapy of Advanced Ovarian Carcinoma: Analysis of Clinical Application Efficacy and Dosimetric Verification Shen, Jing Tao, Yin Jie Guan, Hui Zhen, Hong Nan Dong, Ting Ting Liu, Zhi Kai Zhang, Fu Quan World J Oncol Original Article BACKGROUND: The aim of the study was to evaluate the efficacy of abdominopelvic lymphatic drainage area irradiation (APLN), instead of whole abdominal radiotherapy (WART), in the consolidative radiotherapy of advanced ovarian carcinoma patients. METHODS: We conducted a retrospective analysis collecting 99 patients with locally advanced ovarian cancer treated by APLN with 45 - 50 Gy/25- 28 fractions/5-7#, instead of WART. We evaluated the clinical outcome of APLN. Five patients were selected for dosimetric verifications verses WART (30 Gy/20 fractions). The normal tissue complication probability (NTCP) was calculated for the two treatment methods. RESULTS: The mean follow-up time was 64.10 months (5.5 - 113.2 months), after APLN consolidative radiotherapy, 1-, 3-, and 5-year overall survival (OS) was 87.9%, 81.3%, and 61.5%, median disease-free survival (DFS) was 40.8 months, 5-year local recurrence free survival (LRFS) was 75.9%, and 5-year distant metastasis free survival (DMFS) was 49.2%. One patient died due to intestinal perforation. Local recurrence in the area between WART and APLN was rare (3/99 patients). The number of surgical procedures < 2 was an independent risk factor for LRFS (P = 0.023). Dosimetric comparison showed that comparing with WART, APLN significantly reduced the organ at risk (OAR) dose: 25.37 ± 3.63 Gy (25%) for liver, 8.77 ± 5.03 Gy (25%) for kidney, 8.14 ± 1.51 Gy (25%) for small intestine, etc. NTCP was reduced by 0.04-1.04% for liver, kidney, and small intestine. CONCLUSION: For consolidative radiotherapy in locally advanced ovarian cancer, APLN (intensity-modulated radiotherapy 45 - 50 Gy/25 - 28 fractions) could be an alternative to WART, resulting in excellent LRFS and DFS, with acceptable toxicities, comparing with previous literature reports. Dosimetric analysis also showed the benefits of APLN in NTCP. Elmer Press 2022-06 2022-06-22 /pmc/articles/PMC9239501/ /pubmed/35837318 http://dx.doi.org/10.14740/wjon1454 Text en Copyright 2022, Shen et al. https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Shen, Jing Tao, Yin Jie Guan, Hui Zhen, Hong Nan Dong, Ting Ting Liu, Zhi Kai Zhang, Fu Quan Abdominopelvic Lymphatic Drainage Area Irradiation for Consolidative Radiotherapy of Advanced Ovarian Carcinoma: Analysis of Clinical Application Efficacy and Dosimetric Verification |
title | Abdominopelvic Lymphatic Drainage Area Irradiation for Consolidative Radiotherapy of Advanced Ovarian Carcinoma: Analysis of Clinical Application Efficacy and Dosimetric Verification |
title_full | Abdominopelvic Lymphatic Drainage Area Irradiation for Consolidative Radiotherapy of Advanced Ovarian Carcinoma: Analysis of Clinical Application Efficacy and Dosimetric Verification |
title_fullStr | Abdominopelvic Lymphatic Drainage Area Irradiation for Consolidative Radiotherapy of Advanced Ovarian Carcinoma: Analysis of Clinical Application Efficacy and Dosimetric Verification |
title_full_unstemmed | Abdominopelvic Lymphatic Drainage Area Irradiation for Consolidative Radiotherapy of Advanced Ovarian Carcinoma: Analysis of Clinical Application Efficacy and Dosimetric Verification |
title_short | Abdominopelvic Lymphatic Drainage Area Irradiation for Consolidative Radiotherapy of Advanced Ovarian Carcinoma: Analysis of Clinical Application Efficacy and Dosimetric Verification |
title_sort | abdominopelvic lymphatic drainage area irradiation for consolidative radiotherapy of advanced ovarian carcinoma: analysis of clinical application efficacy and dosimetric verification |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239501/ https://www.ncbi.nlm.nih.gov/pubmed/35837318 http://dx.doi.org/10.14740/wjon1454 |
work_keys_str_mv | AT shenjing abdominopelviclymphaticdrainageareairradiationforconsolidativeradiotherapyofadvancedovariancarcinomaanalysisofclinicalapplicationefficacyanddosimetricverification AT taoyinjie abdominopelviclymphaticdrainageareairradiationforconsolidativeradiotherapyofadvancedovariancarcinomaanalysisofclinicalapplicationefficacyanddosimetricverification AT guanhui abdominopelviclymphaticdrainageareairradiationforconsolidativeradiotherapyofadvancedovariancarcinomaanalysisofclinicalapplicationefficacyanddosimetricverification AT zhenhongnan abdominopelviclymphaticdrainageareairradiationforconsolidativeradiotherapyofadvancedovariancarcinomaanalysisofclinicalapplicationefficacyanddosimetricverification AT dongtingting abdominopelviclymphaticdrainageareairradiationforconsolidativeradiotherapyofadvancedovariancarcinomaanalysisofclinicalapplicationefficacyanddosimetricverification AT liuzhikai abdominopelviclymphaticdrainageareairradiationforconsolidativeradiotherapyofadvancedovariancarcinomaanalysisofclinicalapplicationefficacyanddosimetricverification AT zhangfuquan abdominopelviclymphaticdrainageareairradiationforconsolidativeradiotherapyofadvancedovariancarcinomaanalysisofclinicalapplicationefficacyanddosimetricverification |